NCT01634087

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of Escalating Doses of Oral Itacitinib in Subjects With Stable, Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Itacitinib	Itacitinib administered orally
DRUG	Placebo	Placebo administered orally

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-01-01
• Completion: 2013-02-01
• First posted: 2012-07-06
• Last updated: 2019-03-12

Locations

9 sites across 2 countries: United States, Canada